ET-1 antagonists have proven beneficial in treating pulmonary arterial hypertension (PAH) (Correale et al., 2018), and been shown to reduce proteinuria and potentially improve outcomes in patients with diabetic kidney disease (DKD) (de Zeeuw et al., 2014; Heerspink et al., 2019). The gene discussed is EDN1; the disease is pulmonary arterial hypertension.